...
search icon
iobt-img

IO Biotech Inc, Common Stock

IOBT

NSQ

$0.98

-$0.04

(-3.92%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$65.88M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
85.71K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.10
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.66 L
$1.73 H
$0.98

About IO Biotech Inc, Common Stock

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIOBTSectorS&P500
1-Week Return-2%0.31%4.65%
1-Month Return10.11%-2.35%12.32%
3-Month Return1.03%-7.91%-3.48%
6-Month Return12.06%-6.24%0.38%
1-Year Return-30%-8.86%11.69%
3-Year Return-85.76%2.73%47.55%
5-Year Return-93.74%31.45%100.22%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue--540.00K756.00K849.00K[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":63.6,"profit":true},{"date":"2023-12-31","value":89.05,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit--(540.00K)(756.00K)-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-54000000,"profit":false},{"date":"2023-12-31","value":-75600000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses10.14M41.23M71.42M91.44M95.18M[{"date":"2020-12-31","value":10.66,"profit":true},{"date":"2021-12-31","value":43.32,"profit":true},{"date":"2022-12-31","value":75.04,"profit":true},{"date":"2023-12-31","value":96.08,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(10.14M)(41.23M)(71.42M)(91.44M)(95.18M)[{"date":"2020-12-31","value":-1014500000,"profit":false},{"date":"2021-12-31","value":-4123400000,"profit":false},{"date":"2022-12-31","value":-7142400000,"profit":false},{"date":"2023-12-31","value":-9144300000,"profit":false},{"date":"2024-12-31","value":-9517700000,"profit":false}]
Total Non-Operating Income/Expense(1.92M)(26.94M)2.35M10.93M5.85M[{"date":"2020-12-31","value":-17.6,"profit":false},{"date":"2021-12-31","value":-246.53,"profit":false},{"date":"2022-12-31","value":21.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":53.51,"profit":true}]
Pre-Tax Income(12.04M)(67.81M)(70.19M)(85.23M)(94.05M)[{"date":"2020-12-31","value":-1204200000,"profit":false},{"date":"2021-12-31","value":-6781100000,"profit":false},{"date":"2022-12-31","value":-7018500000,"profit":false},{"date":"2023-12-31","value":-8523100000,"profit":false},{"date":"2024-12-31","value":-9404800000,"profit":false}]
Income Taxes26.00K68.00K1.27M852.00K1.44M[{"date":"2020-12-31","value":1.8,"profit":true},{"date":"2021-12-31","value":4.71,"profit":true},{"date":"2022-12-31","value":88.22,"profit":true},{"date":"2023-12-31","value":59.04,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(12.07M)(67.88M)(71.46M)(86.08M)(95.49M)[{"date":"2020-12-31","value":-1206800000,"profit":false},{"date":"2021-12-31","value":-6787900000,"profit":false},{"date":"2022-12-31","value":-7145800000,"profit":false},{"date":"2023-12-31","value":-8608300000,"profit":false},{"date":"2024-12-31","value":-9549100000,"profit":false}]
Income From Continuous Operations(12.04M)(67.88M)(71.46M)(79.97M)(95.49M)[{"date":"2020-12-31","value":-1204200000,"profit":false},{"date":"2021-12-31","value":-6787900000,"profit":false},{"date":"2022-12-31","value":-7145800000,"profit":false},{"date":"2023-12-31","value":-7997200000,"profit":false},{"date":"2024-12-31","value":-9549100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(12.07M)(67.88M)(71.46M)(86.08M)(95.49M)[{"date":"2020-12-31","value":-1206800000,"profit":false},{"date":"2021-12-31","value":-6787900000,"profit":false},{"date":"2022-12-31","value":-7145800000,"profit":false},{"date":"2023-12-31","value":-8608300000,"profit":false},{"date":"2024-12-31","value":-9549100000,"profit":false}]
EPS (Diluted)(564.30)(531.97)(2.50)(2.16)(1.38)[{"date":"2020-12-31","value":-56430,"profit":false},{"date":"2021-12-31","value":-53197,"profit":false},{"date":"2022-12-31","value":-250,"profit":false},{"date":"2023-12-31","value":-216,"profit":false},{"date":"2024-12-31","value":-137.77,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IOBT
Cash Ratio 2.03
Current Ratio 2.32

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IOBT
ROA (LTM) -70.13%
ROE (LTM) -138.78%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IOBT
Debt Ratio Lower is generally better. Negative is bad. 0.42
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.58

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IOBT
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 1.37
Price/FCF NM
EV/R 0.00
EV/Ebitda 1.36

FAQs

What is IO Biotech Inc share price today?

IO Biotech Inc (IOBT) share price today is $0.98

Can Indians buy IO Biotech Inc shares?

Yes, Indians can buy shares of IO Biotech Inc (IOBT) on Vested. To buy IO Biotech Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IOBT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of IO Biotech Inc be purchased?

Yes, you can purchase fractional shares of IO Biotech Inc (IOBT) via the Vested app. You can start investing in IO Biotech Inc (IOBT) with a minimum investment of $1.

How to invest in IO Biotech Inc shares from India?

You can invest in shares of IO Biotech Inc (IOBT) via Vested in three simple steps:

  • Click on Sign Up or Invest in IOBT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in IO Biotech Inc shares
What is IO Biotech Inc 52-week high and low stock price?

The 52-week high price of IO Biotech Inc (IOBT) is $1.73. The 52-week low price of IO Biotech Inc (IOBT) is $0.66.

What is IO Biotech Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of IO Biotech Inc (IOBT) is 1.37

What is the Market Cap of IO Biotech Inc?

The market capitalization of IO Biotech Inc (IOBT) is $65.88M

What is IO Biotech Inc’s stock symbol?

The stock symbol (or ticker) of IO Biotech Inc is IOBT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top